Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Sevelamer Suspension in Children with End-Stage Renal Disease

Author(s):  McElhiney Linda F

Issue:  Jan/Feb 2007 - Pediatric Patients
View All Articles in Issue

Page(s):  20-24

Sevelamer Suspension in Children with End-Stage Renal Disease Page 1
Sevelamer Suspension in Children with End-Stage Renal Disease Page 2
Sevelamer Suspension in Children with End-Stage Renal Disease Page 3
Sevelamer Suspension in Children with End-Stage Renal Disease Page 4
Sevelamer Suspension in Children with End-Stage Renal Disease Page 5

Download in electronic PDF format for $65

Abstract:  Control of hyperphosphatemia is a major clinical challenge in children with end-stage renal disease. The best treatment option is a calcium-based phosphate binder, but there is evidence that this treatment protocol causes long-term complications, including vascular calcifications. Sevelamer hydrochloride has been shown to be effective in reducing serum phosphorus levels and the calcium-phosphorus ion product in children on maintenance dialysis and may be key in preventing soft-tissue and vascular calcifications in such patients. Until the U.S. Food and Drug Administration approves the use of sevelamer hydrochloride in children undergoing dialysis, and a liquid dosage form becomes available, compounding pharmacists will need to prepare this unique compound for these patients.

Related Keywords: CHILDREN, INFANTS, CHRONIC RENAL FAILURE, KIDNEY FAILURE, END-STAGE RENAL DISEASE, ESRD, HYPERPHOSPHATEMIA, FIXED OIL, RENAGEL, DIALYSIS, PHOSPHORUS, PHOSPHATE BINDERS, SEVELAMER HYDROCHLORIDE, ORAL SUSPENSION, LIQUID PREPARATIONS, DOSAGE FORMS, FORMULATI

Related Categories: FORMULATIONS, NUTRITION AND NUTRICEUTICALS, PEDIATRICS, STABILITIES, COMPATIBILITIES, UROLOGY/URINARY TRACT

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Sevelamer Suspension in Children with End-Stage Renal Disease
McElhiney Linda F
Jan/Feb 2007
Pg. 20-24

Compounded Oral Ketamine for Severe Depression, Anxiety, and Pain in a Hospice Patient with End-stage Chronic Obstructive Pulmonary Disease, Cardiopulmonary Failure, and Severe Renal Insufficiency: A Case Report
McNulty Jack P
, Hahn Kristian
Sep/Oct 2012
Pg. 364-368

Conservative Management of Chronic Kidney Disease in Cats: Recommendations for Veterinarians and Compounding Pharmacists
Meadows Richard L
, Muller George
Sep/Oct 2010
Pg. 382-394

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Stability of Oral Liquid Dosage Forms of Ethacrynic Acid
Gupta Vishnu D
, Ling Jie
May/Jun 2001
Pg. 232-233

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Treating Canine Hepatic Disease
Davidson Gigi S
May/Jun 2003
Pg. 188-191

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
May/Jun 2016
Pg. 247-249

The Treatment of Canine Atopic Disease
Davidson Gigi S
May/Jun 2002
Pg. 210-215

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions